Cardio Diagnostics Showcases Precision Heart Solutions for Employers

LOS ANGELES, CA - July 1, 2026 - Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence. The company recently showcased its innovative approaches to cardiovascular disease prevention, risk assessment, and cost management at multiple national benefits conferences. Cardio's presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management. The company's message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from tools that help identify elevated risk or silent disease before they progress. This preventive focus aligns with broader trends in healthcare, where organizations are increasingly emphasizing population health management and proactive risk reduction.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. The company's latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.

To view the full article, visit https://ibn.fm/6swfk. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results.